Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Sino Biopharmaceutical ( (HK:1177) ).
Sino Biopharmaceutical has announced a leadership change in its corporate governance functions, with long-serving company secretary and authorised representative Mr. Chan Oi Nin Derek stepping down, effective 13 January 2026, and confirming there is no disagreement with the board or issues requiring shareholder attention. He will be succeeded by Ms. Lai Kuen, who joined the company in September 2025 and brings over 17 years of experience in financial audit, capital markets, information disclosure, corporate governance and company secretarial work across major professional services firms and Hong Kong–listed companies, bolstering the group’s compliance capabilities as it navigates ongoing listing and regulatory requirements.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates in the biopharmaceutical sector, focusing on the research, development and commercialisation of pharmaceutical products for the Chinese and broader Asian healthcare markets. The group is overseen by a board comprising six executive directors and five independent non-executive directors, reflecting a governance structure typical of large-cap Hong Kong–listed healthcare companies.
Average Trading Volume: 75,132,543
Technical Sentiment Signal: Buy
Current Market Cap: HK$122.2B
See more data about 1177 stock on TipRanks’ Stock Analysis page.